Nasdaq · Healthcare
Tilray Brands, Inc. (TLRY)
As-reported financials and recent SEC filings for Tilray Brands, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$821.3M
Net income
$-2.19B
Net margin
—
Diluted EPS
$-2.46
ROE
-146.8%
P/E (TTM)
—
Market cap
$560.6M
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $821.3M | $788.9M | $627.1M | $628.4M | $513.1M |
| Gross profit | $240.6M | $223.4M | $147.0M | $116.8M | $123.2M |
| Operating income | $-2.28B | $-174.7M | $-1.37B | $-610.4M | $-132.2M |
| Net income | $-2.19B | $-245.0M | $-1.45B | $-476.8M | $-367.4M |
| Diluted EPS | $-2.46 | $-0.33 | $-2.35 | $-0.99 | $-1.36 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
8-K2026-06-09
View on EDGAR →42026-04-22
View on EDGAR →1442026-04-21
View on EDGAR →8-K2026-04-21
View on EDGAR →424B72026-04-21
View on EDGAR →424B52026-04-15
View on EDGAR →8-K2026-04-15
View on EDGAR →8-K2026-04-15
View on EDGAR →Go deeper on TLRY
Search Tilray Brands, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.